Alzamend Neuro furnishes updated investor presentation for May 2024; no specific new disclosures provided

Alzamend Neuro, Inc.

Filed under Item 7.01 as a Regulation FD disclosure; presentation furnished as Exhibit 99.1.
Presentation covers therapeutic drugs for Alzheimer's and other neurodegenerative/psychiatric disorders.
No financial data, clinical trial results, or milestones explicitly stated in the filing's exhibit text.
Company uses the presentation in meetings with investors, stockholders, and analysts.
Filing emphasizes forward-looking statements and risks; no material operational changes announced.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.